|
|
Office Locations:
|
Two Logan Square 100 N. 18th St., Suite 1930
Philadelphia, PA 19103
Phone: (215)-419-7830
| |
|
|
|
|
|
|
Life Sciences & Healthcare
Medical Device
|
|
|
|
Founded in 2010, New Rhein is a private equity investment firm focused on healthcare therapeutics and medical devices. The firm invests in businesses which utilize proven products in new applications (e.g., new indications, new dosage forms). Products can either be patent protected and branded, non-patent protected and branded, or non-patent protected and non-branded. Companies should generate at least $5M to $50M in revenues and $1M to $10M in operating profit. New Rhein prefers to invest in companies based in Europe, United States, Brazil, and China. The firm's average equity commitment is $10-30M over the duration of an investment.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
